Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
Episodes 16-30 of 64
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
MinuteCE®Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
- advertisement
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
MinuteCE®Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Applications of Emerging Data in Resectable NSCLC
MinuteCE®Applications of Emerging Data in Resectable NSCLC
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
MinuteCE®The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
MinuteCE®Strategies in EGFR-mutated Unresectable Stage III NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MinuteCE®Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
- advertisement
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®MET and Other Emerging Targets in Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
